Endo Pharmaceuticals chops 560 jobs to refocus on cellulite drug launch
Less than a month after inking a $658 million deal to buy out BioSpecifics Technologies, Endo Pharmaceuticals is shuttering multiple manufacturing sites and cutting 560 jobs to refocus on a drug launch in the spring.
The restructuring will occur in phases over the next few years, Endo $ENDP said Thursday. The Dublin-based biotech will gradually exit manufacturing sites in Irvine, CA and Chestnut Ridge, NY, and API manufacturing and bioequivalence study sites in India through the second half of 2022. Plus, it plans on trimming administrative costs by outsourcing “certain transaction processing activities.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters